Modality
Gene Editing
MOA
Cl18.2
Target
PD-L1
Pathway
mTOR
Prostate Ca
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
~Sep 2020
→ ~Dec 2021
Phase 2
Mar 2022
→ May 2031
Phase 2Current
NCT03887663
2,908 pts·Prostate Ca
2022-03→2031-05·Recruiting
2,908 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-275.2y awayPh3 Readout· Prostate Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2031-05-27 · 5.2y away
Prostate Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03887663 | Phase 2/3 | Prostate Ca | Recruiting | 2908 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| MRU-8112 | Merus | Preclinical | PD-L1 |